Unleash the brain's infinite potential
About
Galmeon aims to transform patient care thanks to neuroscience in order to develop non-invasive therapeutic solutions.
Founded in 2025, Galmeon pays tribute to two pioneers in the history of neuroscience:
- Luigi Galvani (18th century), physicist and physician, pioneer of muscle electrophysiology
- Alcmeon of Croton (5th century BC), the first Greek physician to recognise the central role of the brain
Our ambition is to develop solutions that enhance quality of life through the power of the brain.
Our mission
Our project began with an observation: the brain plays a central role in patients' journeys.*
Galmeon addresses a real public health issue: the return to active life (work and sports).
With our therapeutic solutions, we help patients regain optimal mobility faster.
*DOI: 10.1016/j.neuroscience.2024.07.014 / DOI: 10.1016/j.neuroimage.2024.120746
Our Products
We develop software and hardware solutions for healthcare practitioners that integrate AI.
Our goal is to systematize the diagnosis of neuromotor alterations, provide personalised treatments, and ensure patient progress.
These alterations, also known as Arthrogenic Muscle Inhibitions (AMI), are mechanisms developed by the brain following trauma or surgery.
Initially adaptative, they persist in nearly half of all cases, leading to chronic motor disorders and rehabilitation setbacks.
Early identification and treatment are therefore essential.
Our values:
- a strong scientific culture, based on rigorous research protocols
- a technological approach integrating neuroscience and personalised data analysis using artificial intelligence (AI)
- our commitment to developing our technologies in France
We are develop technologies that enable healthcare practitioners (orthopaedic surgeons, sports doctors, physiotherapists, osteopaths) to detect neuromotor alterations in a standardised way before and after surgery.
Early identification makes possible to propose an appropriate treatment protocol.
We develop a solution to solve neuromotor disorders (musculoskeletal disorders, neurology, urology, TMJ) by combining motor imagery with low-frequency sounds.
Based on the principles of Allyane Therapy, this software solution supports practitioners throughout their sessions, ensuring effective, reproducible and sustainable care thanks to patient monitoring.
We develop software solutions that enables healthcare practitioners to track their patients’ progress and adherence in order to maximise the results of the treatment.
team
Cyrille FLEURY
Chairman
Cyrille has held executive positions in publicly traded companies and served as chairman of the Menix Group. Passionate about innovation, he has implemented digital solutions in orthopaedic and dental surgery both in France and internationally.
Cyrille sits on the boards of healthcare companies and on the SNITEM board of directors.
Scientific Advisory Board
Aymeric GUILLOT
University professor
Aymeric has been a researcher in neurophysiology for over twenty years, specializing in visualization and motor imagery to enhance performance in both sports and rehabilitation. His work explores neuroplasticity induced by mental training and involves developing tools to measure its effects.
Recognized both nationally and internationally, his research combines fundamental neuroscience with clinical and sports applications.
Romain LOURSAC
Sports physician, physician for the LOU Rugby professional team
Romain is a sports physician for the iconic Lyon-based rugby club the LOU.
Thanks to his double expertise as a high-level athlete and a healthcare professional, he contributes to Galmeon’s strategy on therapeutic innovations, helping to develop personalized solutions for patients and athletes.